Photodynamic therapy for prostate cancer: a new high-tech method of treatment. Photodynamic therapy - a new approach to treating cancer. The principle of photodynamic therapy lies in the fact that the local effect of an inactive drug is activated by light sources. Non-toxic drug intravenously, laser irradiation with a certain wavelength of exposure leads to the release of reactive oxygen substances that cause cell damage and necrosis of the tumor, with minimal impact on the surrounding tissue. Tukad - plant palladium bakterilno-chlorophyll drug for photodynamic therapy of prostate cancer. Invented by Dr. Avigdor Scherz in 1999 (Israel). Production of the drug carried STEBA BIOTECH NV (France). In the laboratory of Dr. A. Scherz and Y. Salomon showed that photoactivation Tukada intravenous fiber-optic radiation after its introduction, causes oxidative damage to tumor blood vessels, which has caused the tumor ischemia and necrosis. Pharmacokinetic trials were conducted on cell cultures and laboratory animals. Effectiveness Tukada in laboratory animals 90 days after photodynamic therapy with subcutaneous tumors were 73%, with bone tumors - 50%. In an experiment on laboratory animals (dogs), it was demonstrated that therapeutic doses of PDT with Tukadom not cause structural or functional abnormalities of the urethra and rectum. At present, photodynamic therapy with Tukadom used primarily in patients with prostate cancer, who, in spite of deferred radiotherapy, continued progression of the disease, as a last resort. Apparently, further evidence will be expanded. In most patients, photodynamic therapy with Tukadom elimination of cancer cells has led to repeated biopsies and reducing PSA. Authentically speak about the effectiveness and safety of PDT with Tukadom will be only after a randomized clinical trial. Since 2004, began clinical trials Tukada in the treatment of prostate cancer in Canada, France, Britain, Israel and the United States. Perhaps in the future photo-dinamicheksaya therapy is the method of choice in treating patients with prostate cancer.